Ibrance-Faslodex Combo Improves Survival of Advanced Breast Cancer Patients, Phase 3 Trial Shows

Ibrance-Faslodex Combo Improves Survival of Advanced Breast Cancer Patients, Phase 3 Trial Shows
Adding Pfizer’s Ibrance (palbociclib) to standard treatment Faslodex (fulvestrant) significantly extended the survival of advanced breast cancer patients in a Phase 3 clinical trial, researchers report. Called PALOMA-3, the trial  (NCT01942135) specifically tested if patients with hormone-receptor-positive (HR)-positive, human epidermal growth factor 2 (HER2)-negative metastatic breast cancer responded better to the combination than to AstraZeneca's Faslodex alone. Trial findings were published in the study, “Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer,” in The New England Journal of Medicine.” "The results of the study show that it is possible to improve and prolong the life of patients with hormone receptor-positive metastatic breast cancer. We now have solid data to suggest that this treatment should be the new standard of care," lead author Massimo Cristofanilli, MD, said in a press release. Cristofanilli is a professor of hematology/oncology at Northwestern University Feinberg School of Medicine and a Northwestern Medicine physician. Most breast cancers are HR-positive, which means they depend on hormones, such as estrogen, to continue growing. These cancers are generally treated with hormone therapies like Faslodex that prevent estrogen from interacting with its receptor, reducing the growing signals to the tumors. However, after some time, patients can develop resistance to these medications. Ibrance is a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor. Cyclin-dependent kinases are molecules involved in cell division, making them crucial for tumor growth. Therapies that inhibit these molecules tend to work well in combination with hormone therapies. The PALOMA-1 (NCT00721409) and PALOMA-2 (NCT01740427)
Subscribe or to access all post and page content.